D2R / TRP channels
  Name: D(2) dopamine receptor  
  (D2R)
  Official Symbol: DRD2
  
    provided by HGNC
  
  Function:
  
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (By similarity).
Source: Reorganizing the protein space at the Universal Protein Resource (UniProt)
Nucleic Acids Res. 40: D71-D75 (2012).
    | Species | 
        External DB
         
        
       | 
    |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Entrez Gene | UniprotKB | DIP | IntAct | MINT | BioGRID | STRING | IUPHAR-DB | KEGG | OMIM | |
          Human
             
         | 
          1813 | 
          P14416 | 
          DIP-5977N | 
          P14416 | 
          MINT-201447 | 
          108147 | 
          P14416 | 
          hsa:1813 | 
          126450 | 
      |
          Mouse
             
         | 
          13489 | 
          P61168 | 
          MINT-5313868 | 
          199306 | 
          P61168 | 
          mmu:13489 | 
          ||||
          Rat
             
         | 
          24318 | 
          P61169 | 
          DIP-30883N | 
          P61169 | 
          MINT-4792453 | 
          246498 | 
          P61169 | 
          rno:24318 | 
          ||
    Biological Process:
    
      
    - GO:0032147 
 : activation of protein kinase activity  - GO:0021984 
 : adenohypophysis development  - GO:0007195 
 : adenylate cyclase-inhibiting dopamine receptor signaling pathway  - GO:0007628 
 : adult walking behavior  - GO:0050482 
 : arachidonic acid secretion  - GO:0031223 
 : auditory behavior  - GO:0007409 
 : axonogenesis  - GO:0048148 
 : behavioral response to cocaine  - GO:0048149 
 : behavioral response to ethanol  - GO:0048755 
 : branching morphogenesis of a nerve  - GO:0021853 
 : cerebral cortex GABAergic interneuron migration  - GO:0032922 
 : circadian regulation of gene expression  - GO:0042417 
 : dopamine metabolic process  - GO:0051482 
 : elevation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway  - GO:0007631 
 : feeding behavior  - GO:0002031 
 : G-protein coupled receptor internalization  - GO:0007625 
 : grooming behavior  - GO:0007243 
 : intracellular protein kinase cascade  - GO:0007616 
 : long-term memory  - GO:0007194 
 : negative regulation of adenylate cyclase activity  - GO:0045776 
 : negative regulation of blood pressure  - GO:0030336 
 : negative regulation of cell migration  - GO:0008285 
 : negative regulation of cell proliferation  - GO:0042321 
 : negative regulation of circadian sleep/wake cycle, sleep  - GO:0060160 
 : negative regulation of dopamine receptor signaling pathway  - GO:0046676 
 : negative regulation of insulin secretion  - GO:0051898 
 : negative regulation of protein kinase B signaling cascade  - GO:0050709 
 : negative regulation of protein secretion  - GO:0051967 
 : negative regulation of synaptic transmission, glutamatergic  - GO:1901386 
 : negative regulation of voltage-gated calcium channel activity  - GO:0001976 
 : neurological system process involved in regulation of systemic arterial blood pressure  - GO:0007270 
 : neuron-neuron synaptic transmission  - GO:0030432 
 : peristalsis  - GO:0046488 
 : phosphatidylinositol metabolic process  - GO:0060158 
 : phospholipase C-activating dopamine receptor signaling pathway  - GO:0043473 
 : pigmentation  - GO:0051586 
 : positive regulation of dopamine uptake involved in synaptic transmission  - GO:0070374 
 : positive regulation of ERK1 and ERK2 cascade  - GO:0045745 
 : positive regulation of G-protein coupled receptor protein signaling pathway  - GO:0060124 
 : positive regulation of growth hormone secretion  - GO:0040018 
 : positive regulation of multicellular organism growth  - GO:0002052 
 : positive regulation of neuroblast proliferation  - GO:0002092 
 : positive regulation of receptor internalization  - GO:0035815 
 : positive regulation of renal sodium excretion  - GO:0045944 
 : positive regulation of transcription from RNA polymerase II promoter  - GO:0035810 
 : positive regulation of urine volume  - GO:0060134 
 : prepulse inhibition  - GO:0008104 
 : protein localization  - GO:0051481 
 : reduction of cytosolic calcium ion concentration  - GO:0030814 
 : regulation of cAMP metabolic process  - GO:0014059 
 : regulation of dopamine secretion  - GO:0002027 
 : regulation of heart rate  - GO:0048169 
 : regulation of long-term neuronal synaptic plasticity  - GO:0043666 
 : regulation of phosphoprotein phosphatase activity  - GO:0043266 
 : regulation of potassium ion transport  - GO:0002028 
 : regulation of sodium ion transport  - GO:0032228 
 : regulation of synaptic transmission, GABAergic  - GO:0051209 
 : release of sequestered calcium ion into cytosol  - GO:0001975 
 : response to amphetamine  - GO:0048678 
 : response to axon injury  - GO:0042493 
 : response to drug  - GO:0034776 
 : response to histamine  - GO:0001666 
 : response to hypoxia  - GO:0010039 
 : response to iron ion  - GO:0043278 
 : response to morphine  - GO:0035094 
 : response to nicotine  - GO:0009636 
 : response to toxin  - GO:0007608 
 : sensory perception of smell  - GO:0007416 
 : synapse assembly  - GO:0001963 
 : synaptic transmission, dopaminergic  - GO:0001659 
 : temperature homeostasis  - GO:0008542 
 : visual learning  - GO:0016055 
 : Wnt receptor signaling pathway  
Source: The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat. Genet.. May 2000;25(1):25-9.
World Wide Web URL: http://www.geneontology.org/
World Wide Web URL: http://www.geneontology.org/
    Disease:
    
      
    - OMIM:126450 
 :
 Dystonia, myoclonic
(OMIM:159900 
) 
 
Source: Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, 
Johns Hopkins University (Baltimore, MD), May, 2012. 
World Wide Web URL: http://omim.org/
World Wide Web URL: http://omim.org/
        Screening
        Validation: In vitro validation
        Validation: In vivo validation
        Characterization
        Functional consequence
     | 
    
        top
     | 
  
Screening
         
       | 
    ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Experimental screening | Non-experimental screening | Reference | ||||||||
| TRP channel construct | Interactor source | |||||||||
| TRP channel | Interactor | Method | Species | Region | Species | Organ/tissue | Sample type | |||
| TRPC1 | 
             
           | 
        D2R | Yeast two-hybrid | Not used as a bait | Human | Fetal brain | cDNA library | 18261457 | ||
| TRPC4 | 
             
           | 
        D2R | Inference | Prediction | 18261457 | |||||
| TRPC5 | 
             
           | 
        D2R | Inference | Prediction | 18261457 | |||||
  (
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
  
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
        Screening
        Validation: In vitro validation
        Validation: In vivo validation
        Characterization
        Functional consequence
     | 
    
        top
     | 
  
Validation: In vitro validation
      
         
       | 
    ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Assay with recombinant proteins | Reference | |||||||||
| TRP channel construct | Interactor construct | |||||||||
| TRP channel | Interactor | Method | Species | Region | Expression system | Species | Region | Expression system | ||
| TRPC1 | 
             
           | 
        D2R | Fusion protein-pull down assay | Human | 638-759 | E. coli | Human | 131-151 | E. coli | 18261457 | 
| TRPC4 | 
             
           | 
        D2R | Fusion protein-pull down assay | Human | 621-893 | E. coli | Human | 131-151 | E. coli | 18261457 | 
| TRPC5 | 
             
           | 
        D2R | Fusion protein-pull down assay | Human | 619-973 | E. coli | Human | 131-151 | E. coli | 18261457 | 
  (
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
  
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
        Screening
        Validation: In vitro validation
        Validation: In vivo validation
        Characterization
        Functional consequence
     | 
    
        top
     | 
  
Validation: In vivo validation
         
       | 
    ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Assay with endogenous proteins | Assay with overexpressed proteins | Reference | ||||||||
| Cell or tissue | Cell or tissue | TRP channel construct | Interactor construct | |||||||
| TRP channel | Interactor | Method | Species | Region | Species | Region | ||||
| TRPC1 | 
             
           | 
        D2R | Co-immunofluorescence staining | Monkey prefrontal cortex | 18261457 | |||||
| TRPC1 | 
             
           | 
        D2R | Co-immunoprecipitation | Rat striatal tissue | 18261457 | |||||
| TRPC1 | 
             
           | 
        D2R | Co-immunoprecipitation | Rat cortex tissue | 18261457 | |||||
  (
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
  
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
        Screening
        Validation: In vitro validation
        Validation: In vivo validation
        Characterization
        Functional consequence
     | 
    
        top
     | 
  
Characterization
         
       | 
    ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Binding region mapping | Stoichiometry | Affinity (Kd) | Reference | |||||||
| TRP channel | Interactor | |||||||||
| TRP channel | Interactor | Method | Species | Region | Species | Region | ||||
| TRPC1 | 
             
           | 
        D2R | Yeast two-hybrid | Human | 726-745 | Human | 131-151 | 18261457 | ||
| TRPC4 | 
             
           | 
        D2R | Yeast two-hybrid | Human | 712-731 | Human | 131-151 | 18261457 | ||
| TRPC5 | 
             
           | 
        D2R | Yeast two-hybrid | Human | 719-738 | Human | 131-151 | 18261457 | ||
  (
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
  
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
        Screening
        Validation: In vitro validation
        Validation: In vivo validation
        Characterization
        Functional consequence
     | 
    
        top
     | 
  
Functional consequence
         
       | 
    ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRP channel | Interactor | Method | Post-translational modification | Subcellular trafficking | Activity | Reference | ||||||
| TRPC1 | 
             
           | 
        D2R | Cell surface biotinylation | Increase in plasma membrane level | 18261457 | |||||||
  (
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)
  
: 
  click the arrow icon to show interactions only between the corresponding TRP channel and the interactor)







 Screening